With REACH updates anticipated in 2025, the European Commission, ECHA and EFSA are sharpening their focus on endocrine and thyroid disruption data to strengthen chemical safety assessments.

This evolution reflects growing regulatory and scientific consensus that mechanistic endocrine data, particularly for thyroid pathways are essential for robust human and environmental risk assessments.

As the regulatory landscape evolves and the demand for testing grows, laboratory capacity will tighten and costs may rise. Early planning is therefore critical to avoid delays, control costs and ensure readiness for submissions.

Expertise in endocrine disruption assays

With extensive experience in regulatory and research needs, the scientific team at Concept Life Sciences will partner with you to navigate this anticipated change through rigorous, regulatory-aligned testing to provide:

Extensive suite of endocrine disruption assays – in vitro and ex vivo assays covering estrogen, androgen and steroidogenesis pathways (EAS), designed in line with OECD Test Guidelines and the OECD Conceptual Framework for endocrine disruptor assessment. These assays enable cross-species comparison and exploration of species-specific mechanisms of endocrine modulation, helping to evaluate the relevance of in vivo toxicology findings.

Thyroid disruption testing panel – A broad suite of validated assays targeting key molecular mechanisms, including NIS, TPO, Deiodinase, UGT and transthyretin binding assays. Explore our thyroid assays

Regulatory guidance – Fit-for-purpose strategies aligned with ECHA and EFSA guidance on identifying endocrine disruptors under REACH and CLP.

Trusted scientific support – Focused expert team with experienced toxicologists sharing deep knowledge to provide clear, defensible results to support regulatory dossiers and give you confidence and clarity in data interpretation for actionable sight.

Now is the time to: